1734 related articles for article (PubMed ID: 24450890)
1. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease.
Doody RS; Thomas RG; Farlow M; Iwatsubo T; Vellas B; Joffe S; Kieburtz K; Raman R; Sun X; Aisen PS; Siemers E; Liu-Seifert H; Mohs R; ;
N Engl J Med; 2014 Jan; 370(4):311-21. PubMed ID: 24450890
[TBL] [Abstract][Full Text] [Related]
2. Trial of Solanezumab for Mild Dementia Due to Alzheimer's Disease.
Honig LS; Vellas B; Woodward M; Boada M; Bullock R; Borrie M; Hager K; Andreasen N; Scarpini E; Liu-Seifert H; Case M; Dean RA; Hake A; Sundell K; Poole Hoffmann V; Carlson C; Khanna R; Mintun M; DeMattos R; Selzler KJ; Siemers E
N Engl J Med; 2018 Jan; 378(4):321-330. PubMed ID: 29365294
[TBL] [Abstract][Full Text] [Related]
3. Phase 3 solanezumab trials: Secondary outcomes in mild Alzheimer's disease patients.
Siemers ER; Sundell KL; Carlson C; Case M; Sethuraman G; Liu-Seifert H; Dowsett SA; Pontecorvo MJ; Dean RA; Demattos R
Alzheimers Dement; 2016 Feb; 12(2):110-120. PubMed ID: 26238576
[TBL] [Abstract][Full Text] [Related]
4. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.
Salloway S; Sperling R; Fox NC; Blennow K; Klunk W; Raskind M; Sabbagh M; Honig LS; Porsteinsson AP; Ferris S; Reichert M; Ketter N; Nejadnik B; Guenzler V; Miloslavsky M; Wang D; Lu Y; Lull J; Tudor IC; Liu E; Grundman M; Yuen E; Black R; Brashear HR;
N Engl J Med; 2014 Jan; 370(4):322-33. PubMed ID: 24450891
[TBL] [Abstract][Full Text] [Related]
5. Lecanemab in Early Alzheimer's Disease.
van Dyck CH; Swanson CJ; Aisen P; Bateman RJ; Chen C; Gee M; Kanekiyo M; Li D; Reyderman L; Cohen S; Froelich L; Katayama S; Sabbagh M; Vellas B; Watson D; Dhadda S; Irizarry M; Kramer LD; Iwatsubo T
N Engl J Med; 2023 Jan; 388(1):9-21. PubMed ID: 36449413
[TBL] [Abstract][Full Text] [Related]
6. Randomized Trial of Verubecestat for Mild-to-Moderate Alzheimer's Disease.
Egan MF; Kost J; Tariot PN; Aisen PS; Cummings JL; Vellas B; Sur C; Mukai Y; Voss T; Furtek C; Mahoney E; Harper Mozley L; Vandenberghe R; Mo Y; Michelson D
N Engl J Med; 2018 May; 378(18):1691-1703. PubMed ID: 29719179
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial.
Wilcock GK; Black SE; Hendrix SB; Zavitz KH; Swabb EA; Laughlin MA;
Lancet Neurol; 2008 Jun; 7(6):483-93. PubMed ID: 18450517
[TBL] [Abstract][Full Text] [Related]
8. A phase 3 trial of semagacestat for treatment of Alzheimer's disease.
Doody RS; Raman R; Farlow M; Iwatsubo T; Vellas B; Joffe S; Kieburtz K; He F; Sun X; Thomas RG; Aisen PS; ; Siemers E; Sethuraman G; Mohs R;
N Engl J Med; 2013 Jul; 369(4):341-50. PubMed ID: 23883379
[TBL] [Abstract][Full Text] [Related]
9. Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimer's disease (BLAZE).
Salloway S; Honigberg LA; Cho W; Ward M; Friesenhahn M; Brunstein F; Quartino A; Clayton D; Mortensen D; Bittner T; Ho C; Rabe C; Schauer SP; Wildsmith KR; Fuji RN; Suliman S; Reiman EM; Chen K; Paul R
Alzheimers Res Ther; 2018 Sep; 10(1):96. PubMed ID: 30231896
[TBL] [Abstract][Full Text] [Related]
10. Donanemab in Early Alzheimer's Disease.
Mintun MA; Lo AC; Duggan Evans C; Wessels AM; Ardayfio PA; Andersen SW; Shcherbinin S; Sparks J; Sims JR; Brys M; Apostolova LG; Salloway SP; Skovronsky DM
N Engl J Med; 2021 May; 384(18):1691-1704. PubMed ID: 33720637
[TBL] [Abstract][Full Text] [Related]
11. Cognitive Impairment Precedes and Predicts Functional Impairment in Mild Alzheimer's Disease.
Liu-Seifert H; Siemers E; Price K; Han B; Selzler KJ; Henley D; Sundell K; Aisen P; Cummings J; Raskin J; Mohs R;
J Alzheimers Dis; 2015; 47(1):205-14. PubMed ID: 26402769
[TBL] [Abstract][Full Text] [Related]
12. Utilization of Observational Data as a Proxy Cohort for Comparison Purposes with Open-Label Study Results: An Example from Alzheimer's Disease.
Reed C; Happich M; Raskin J; Tockhorn-Heidenreich A; Belger M
J Prev Alzheimers Dis; 2019; 6(2):90-99. PubMed ID: 30756115
[TBL] [Abstract][Full Text] [Related]
13. Trial of Solanezumab in Preclinical Alzheimer's Disease.
Sperling RA; Donohue MC; Raman R; Rafii MS; Johnson K; Masters CL; van Dyck CH; Iwatsubo T; Marshall GA; Yaari R; Mancini M; Holdridge KC; Case M; Sims JR; Aisen PS;
N Engl J Med; 2023 Sep; 389(12):1096-1107. PubMed ID: 37458272
[TBL] [Abstract][Full Text] [Related]
14. Bapineuzumab for mild to moderate Alzheimer's disease in two global, randomized, phase 3 trials.
Vandenberghe R; Rinne JO; Boada M; Katayama S; Scheltens P; Vellas B; Tuchman M; Gass A; Fiebach JB; Hill D; Lobello K; Li D; McRae T; Lucas P; Evans I; Booth K; Luscan G; Wyman BT; Hua L; Yang L; Brashear HR; Black RS;
Alzheimers Res Ther; 2016 May; 8(1):18. PubMed ID: 27176461
[TBL] [Abstract][Full Text] [Related]
15. Safety and biomarker effects of solanezumab in patients with Alzheimer's disease.
Farlow M; Arnold SE; van Dyck CH; Aisen PS; Snider BJ; Porsteinsson AP; Friedrich S; Dean RA; Gonzales C; Sethuraman G; DeMattos RB; Mohs R; Paul SM; Siemers ER
Alzheimers Dement; 2012 Jul; 8(4):261-71. PubMed ID: 22672770
[TBL] [Abstract][Full Text] [Related]
16. Alzheimer's Disease Assessment Scale-Cognitive subscale variants in mild cognitive impairment and mild Alzheimer's disease: change over time and the effect of enrichment strategies.
Podhorna J; Krahnke T; Shear M; Harrison JE;
Alzheimers Res Ther; 2016 Feb; 8():8. PubMed ID: 26868820
[TBL] [Abstract][Full Text] [Related]
17. Cognitive and functional decline and their relationship in patients with mild Alzheimer's dementia.
Liu-Seifert H; Siemers E; Sundell K; Price K; Han B; Selzler K; Aisen P; Cummings J; Raskin J; Mohs R
J Alzheimers Dis; 2015; 43(3):949-55. PubMed ID: 25125457
[TBL] [Abstract][Full Text] [Related]
18. Grasping at straws: the failure of solanezumab to modify mild Alzheimer's disease.
Doggrell SA
Expert Opin Biol Ther; 2018 Dec; 18(12):1189-1192. PubMed ID: 30376649
[TBL] [Abstract][Full Text] [Related]
19. Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial.
Lannfelt L; Blennow K; Zetterberg H; Batsman S; Ames D; Harrison J; Masters CL; Targum S; Bush AI; Murdoch R; Wilson J; Ritchie CW;
Lancet Neurol; 2008 Sep; 7(9):779-86. PubMed ID: 18672400
[TBL] [Abstract][Full Text] [Related]
20. Two Phase 3 Trials of Gantenerumab in Early Alzheimer's Disease.
Bateman RJ; Smith J; Donohue MC; Delmar P; Abbas R; Salloway S; Wojtowicz J; Blennow K; Bittner T; Black SE; Klein G; Boada M; Grimmer T; Tamaoka A; Perry RJ; Turner RS; Watson D; Woodward M; Thanasopoulou A; Lane C; Baudler M; Fox NC; Cummings JL; Fontoura P; Doody RS;
N Engl J Med; 2023 Nov; 389(20):1862-1876. PubMed ID: 37966285
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]